Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celera Genomics (CRA) -- Ignore unavailable to you. Want to Upgrade?

To: allen menglin chen who wrote (352)	5/11/2000 10:08:00 PM
From: gao seng	Read Replies (1) \| Respond to of 746

That and nigel's post today really are proof positive that the public funded efforts are a joke. That doesn't mean that I was wrong about DT and they are now hottest company in town. I still think their PR was overly hyped. You 1 big digger from nigels post: For example, when Chromosome 22 was published last December, the Human Genome Project scientists predicted we'd find 545 genes on that chromosome. But because we'd actually sequenced the genes at Incyte, we knew that over 1,000 of our genes would match that chromosome. So they missed nearly half of them. Don't laugh. They admit it. It's not like they don't know about this problem. In fact, they said in their paper that they wished they had a transcribed gene sequence database, which is exactly what we have. And that, of course, is why almost all the major drug and biotechnology companies subscribe to our database. salon.com